Clinical Trial Update: Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating cidabenamide as maintenance therapy after allogeneic hematopoietic cell transplantation in patients with intermediate/high-risk ac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Cidabenamide (Cidabenamide)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Allogeneic Hematopoietic Cell Transplantation (HCT), AML (Acute Myeloid Leukemia) | Phase 2 | Status: RECRUITING